Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01179048
Registration number
NCT01179048
Ethics application status
Date submitted
6/08/2010
Date registered
10/08/2010
Date last updated
17/07/2019
Titles & IDs
Public title
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
Query!
Scientific title
A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
Query!
Secondary ID [1]
0
0
2009-012201-19
Query!
Secondary ID [2]
0
0
EX2211-3748
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
LEADER®
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes
0
0
Query!
Diabetes Mellitus, Type 2
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - liraglutide
Treatment: Drugs - placebo
Experimental: Liraglutide -
Placebo comparator: Placebo -
Treatment: Drugs: liraglutide
Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Treatment: Drugs: placebo
Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)
Query!
Assessment method [1]
0
0
Time from randomisation to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite cardiovascular outcome). The percentage of subjects experiencing a first event of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite cardiovascular outcome) is presented.
Query!
Timepoint [1]
0
0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Query!
Secondary outcome [1]
0
0
Time From Rand. to First Occurrence of an Expanded Composite Cardiovascular Outcome Defined as Either Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, Revascularisation, Hospitalisation for Unstable Angina or for Heart Failure.
Query!
Assessment method [1]
0
0
Time from randomisation to first occurrence of an expanded composite cardiovascular outcome defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or for heart failure. The percentage of subjects experiencing first occurrence of an expanded composite cardiovascular outcome defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or for heart failure is presented.
Query!
Timepoint [1]
0
0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Query!
Secondary outcome [2]
0
0
Time From Randomisation to All Cause Death
Query!
Assessment method [2]
0
0
Time from randomisation to all cause death. The percentage of subjects with a death by any cause (all-cause death) is presented.
Query!
Timepoint [2]
0
0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Query!
Secondary outcome [3]
0
0
Time From Randomisation to Each Individual Component of the Expanded Composite Cardiovascular Outcome
Query!
Assessment method [3]
0
0
Time from randomisation to each individual component of the expanded composite cardiovascular outcome. The percentage of subjects experiencing each of the individual component of the expanded composite cardiovascular outcome (defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or heart failure) is presented.
Query!
Timepoint [3]
0
0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Query!
Secondary outcome [4]
0
0
Time From Randomisation to First Occurrence of a Composite Microvascular Outcome
Query!
Assessment method [4]
0
0
Time from randomisation to first occurrence of a composite microvascular outcome, defined as any one of the following:
* new onset of persistent macroalbuminuria
* persistent doubling of serum creatinine
* need for continuous renal replacement therapy
* death due to renal disease
* need for retinal photocoagulation or treatment with intravitreal agents
* vitreous haemorrhage
* diabetes-related blindness
The percentage of subjects experiencing a first occurrence of a composite microvascular outcome is presented.
Query!
Timepoint [4]
0
0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Query!
Secondary outcome [5]
0
0
Time From Randomisation to Each Individual Component of the Composite Microvascular Outcome and to the Retinopathy and Nephropathy Composite Outcomes Separately.
Query!
Assessment method [5]
0
0
Time from randomisation to each individual component of the composite microvascular outcome and to the retinopathy and nephropathy composite outcomes separately. The percentage of subjects experiencing each individual component of the composite microvascular outcome are presented.
Query!
Timepoint [5]
0
0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Query!
Eligibility
Key inclusion criteria
- Type 2 diabetes - Age min. 50 years at screening and concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or chronic heart failure OR age min. 60 years at screening and other specified risk factors of cardiovascular disease - HbA1c: 7.0% or above - Anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s)
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Type 1 diabetes - Use of a glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP-4) inhibitor within the 3 months prior to screening (trial start) - Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Short-term use of other insulin during this period in connection with intercurrent illness is allowed, at Investigator's discretion
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/08/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
17/12/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
9341
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
Novo Nordisk Investigational Site - Blacktown
Query!
Recruitment hospital [2]
0
0
Novo Nordisk Investigational Site - Douglas
Query!
Recruitment hospital [3]
0
0
Novo Nordisk Investigational Site - Herston
Query!
Recruitment hospital [4]
0
0
Novo Nordisk Investigational Site - Meadowbrook
Query!
Recruitment hospital [5]
0
0
Novo Nordisk Investigational Site - Keswick
Query!
Recruitment hospital [6]
0
0
Novo Nordisk Investigational Site - Oaklands Park
Query!
Recruitment hospital [7]
0
0
Novo Nordisk Investigational Site - Hobart
Query!
Recruitment hospital [8]
0
0
Novo Nordisk Investigational Site - Box Hill
Query!
Recruitment hospital [9]
0
0
Novo Nordisk Investigational Site - Fitzroy
Query!
Recruitment hospital [10]
0
0
Novo Nordisk Investigational Site - Fremantle
Query!
Recruitment postcode(s) [1]
0
0
2148 - Blacktown
Query!
Recruitment postcode(s) [2]
0
0
4814 - Douglas
Query!
Recruitment postcode(s) [3]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [4]
0
0
4131 - Meadowbrook
Query!
Recruitment postcode(s) [5]
0
0
5035 - Keswick
Query!
Recruitment postcode(s) [6]
0
0
5046 - Oaklands Park
Query!
Recruitment postcode(s) [7]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [8]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [9]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [10]
0
0
6160 - Fremantle
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Delaware
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Iowa
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Montana
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nebraska
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New Hampshire
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New Jersey
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New York
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
North Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Ohio
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Oklahoma
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Pennsylvania
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
South Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Tennessee
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Utah
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Vermont
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Washington
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Wisconsin
Query!
Country [34]
0
0
Austria
Query!
State/province [34]
0
0
Graz
Query!
Country [35]
0
0
Austria
Query!
State/province [35]
0
0
Wien
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Edegem
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Gent
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Leuven
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Liège
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Ceara
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
Goias
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Parana
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
Para
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
Rio Grande Do Sul
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
Sao Paulo
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Aracajú
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
Belo Horizonte
Query!
Country [48]
0
0
Brazil
Query!
State/province [48]
0
0
Campinas
Query!
Country [49]
0
0
Brazil
Query!
State/province [49]
0
0
Curitiba
Query!
Country [50]
0
0
Brazil
Query!
State/province [50]
0
0
Fortaleza
Query!
Country [51]
0
0
Brazil
Query!
State/province [51]
0
0
Goiânia
Query!
Country [52]
0
0
Brazil
Query!
State/province [52]
0
0
Joinville
Query!
Country [53]
0
0
Brazil
Query!
State/province [53]
0
0
Marília
Query!
Country [54]
0
0
Brazil
Query!
State/province [54]
0
0
Porto Alegre
Query!
Country [55]
0
0
Brazil
Query!
State/province [55]
0
0
Recife
Query!
Country [56]
0
0
Brazil
Query!
State/province [56]
0
0
Rio de Janeiro
Query!
Country [57]
0
0
Brazil
Query!
State/province [57]
0
0
Santos
Query!
Country [58]
0
0
Brazil
Query!
State/province [58]
0
0
São Paulo
Query!
Country [59]
0
0
Canada
Query!
State/province [59]
0
0
Alberta
Query!
Country [60]
0
0
Canada
Query!
State/province [60]
0
0
British Columbia
Query!
Country [61]
0
0
Canada
Query!
State/province [61]
0
0
Manitoba
Query!
Country [62]
0
0
Canada
Query!
State/province [62]
0
0
Newfoundland and Labrador
Query!
Country [63]
0
0
Canada
Query!
State/province [63]
0
0
Nova Scotia
Query!
Country [64]
0
0
Canada
Query!
State/province [64]
0
0
Ontario
Query!
Country [65]
0
0
Canada
Query!
State/province [65]
0
0
Quebec
Query!
Country [66]
0
0
China
Query!
State/province [66]
0
0
Beijing
Query!
Country [67]
0
0
China
Query!
State/province [67]
0
0
Fujian
Query!
Country [68]
0
0
China
Query!
State/province [68]
0
0
Guangdong
Query!
Country [69]
0
0
China
Query!
State/province [69]
0
0
Jiangsu
Query!
Country [70]
0
0
China
Query!
State/province [70]
0
0
Shandong
Query!
Country [71]
0
0
China
Query!
State/province [71]
0
0
Shanghai
Query!
Country [72]
0
0
Czechia
Query!
State/province [72]
0
0
Plzen
Query!
Country [73]
0
0
Czechia
Query!
State/province [73]
0
0
Praha
Query!
Country [74]
0
0
Denmark
Query!
State/province [74]
0
0
Aalborg
Query!
Country [75]
0
0
Denmark
Query!
State/province [75]
0
0
Esbjerg
Query!
Country [76]
0
0
Denmark
Query!
State/province [76]
0
0
Gentofte
Query!
Country [77]
0
0
Denmark
Query!
State/province [77]
0
0
Hvidovre
Query!
Country [78]
0
0
Denmark
Query!
State/province [78]
0
0
Odense
Query!
Country [79]
0
0
Denmark
Query!
State/province [79]
0
0
Århus C
Query!
Country [80]
0
0
Finland
Query!
State/province [80]
0
0
Kuopio
Query!
Country [81]
0
0
Finland
Query!
State/province [81]
0
0
Lahti
Query!
Country [82]
0
0
Finland
Query!
State/province [82]
0
0
Oulu
Query!
Country [83]
0
0
Finland
Query!
State/province [83]
0
0
Tampere
Query!
Country [84]
0
0
Finland
Query!
State/province [84]
0
0
Vantaa
Query!
Country [85]
0
0
France
Query!
State/province [85]
0
0
Corbeil Essonnes
Query!
Country [86]
0
0
France
Query!
State/province [86]
0
0
Jarny
Query!
Country [87]
0
0
France
Query!
State/province [87]
0
0
Nimes
Query!
Country [88]
0
0
France
Query!
State/province [88]
0
0
Paris
Query!
Country [89]
0
0
Germany
Query!
State/province [89]
0
0
Angermünde/OT Wolletz
Query!
Country [90]
0
0
Germany
Query!
State/province [90]
0
0
Aschaffenburg
Query!
Country [91]
0
0
Germany
Query!
State/province [91]
0
0
Berlin
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Dillingen
Query!
Country [93]
0
0
Germany
Query!
State/province [93]
0
0
Dresden
Query!
Country [94]
0
0
Germany
Query!
State/province [94]
0
0
Elsterwerda
Query!
Country [95]
0
0
Germany
Query!
State/province [95]
0
0
Essen
Query!
Country [96]
0
0
Germany
Query!
State/province [96]
0
0
Falkensee
Query!
Country [97]
0
0
Germany
Query!
State/province [97]
0
0
Gifhorn
Query!
Country [98]
0
0
Germany
Query!
State/province [98]
0
0
Hamburg
Query!
Country [99]
0
0
Germany
Query!
State/province [99]
0
0
Karlsbad
Query!
Country [100]
0
0
Germany
Query!
State/province [100]
0
0
Leipzig
Query!
Country [101]
0
0
Germany
Query!
State/province [101]
0
0
Ludwigshafen
Query!
Country [102]
0
0
Germany
Query!
State/province [102]
0
0
Mannheim
Query!
Country [103]
0
0
Germany
Query!
State/province [103]
0
0
München
Query!
Country [104]
0
0
Germany
Query!
State/province [104]
0
0
Oldenburg
Query!
Country [105]
0
0
Germany
Query!
State/province [105]
0
0
Saint Ingbert-Oberwürzbach
Query!
Country [106]
0
0
Germany
Query!
State/province [106]
0
0
Schkeuditz
Query!
Country [107]
0
0
Germany
Query!
State/province [107]
0
0
Schweinfurt
Query!
Country [108]
0
0
Germany
Query!
State/province [108]
0
0
Ulm
Query!
Country [109]
0
0
Germany
Query!
State/province [109]
0
0
Villingen-Schwenningen
Query!
Country [110]
0
0
Germany
Query!
State/province [110]
0
0
Wangen
Query!
Country [111]
0
0
Greece
Query!
State/province [111]
0
0
Athens
Query!
Country [112]
0
0
Greece
Query!
State/province [112]
0
0
Crete
Query!
Country [113]
0
0
Greece
Query!
State/province [113]
0
0
Thessaloniki
Query!
Country [114]
0
0
India
Query!
State/province [114]
0
0
Andhra Pradesh
Query!
Country [115]
0
0
India
Query!
State/province [115]
0
0
Assam
Query!
Country [116]
0
0
India
Query!
State/province [116]
0
0
Haryana
Query!
Country [117]
0
0
India
Query!
State/province [117]
0
0
Karnataka
Query!
Country [118]
0
0
India
Query!
State/province [118]
0
0
Kerala
Query!
Country [119]
0
0
India
Query!
State/province [119]
0
0
Madhya Pradesh
Query!
Country [120]
0
0
India
Query!
State/province [120]
0
0
Maharashtra
Query!
Country [121]
0
0
India
Query!
State/province [121]
0
0
Punjab
Query!
Country [122]
0
0
India
Query!
State/province [122]
0
0
Tamil Nadu
Query!
Country [123]
0
0
India
Query!
State/province [123]
0
0
West Bengal
Query!
Country [124]
0
0
India
Query!
State/province [124]
0
0
Thriruvananthapuram
Query!
Country [125]
0
0
Ireland
Query!
State/province [125]
0
0
Dublin 9
Query!
Country [126]
0
0
Ireland
Query!
State/province [126]
0
0
Dublin
Query!
Country [127]
0
0
Israel
Query!
State/province [127]
0
0
Haifa
Query!
Country [128]
0
0
Israel
Query!
State/province [128]
0
0
Jerusalem
Query!
Country [129]
0
0
Israel
Query!
State/province [129]
0
0
Petah-Tikva
Query!
Country [130]
0
0
Israel
Query!
State/province [130]
0
0
Tel Hashomer
Query!
Country [131]
0
0
Italy
Query!
State/province [131]
0
0
Bologna
Query!
Country [132]
0
0
Italy
Query!
State/province [132]
0
0
Catanzaro
Query!
Country [133]
0
0
Italy
Query!
State/province [133]
0
0
Chieti
Query!
Country [134]
0
0
Italy
Query!
State/province [134]
0
0
Firenze
Query!
Country [135]
0
0
Italy
Query!
State/province [135]
0
0
Latina
Query!
Country [136]
0
0
Italy
Query!
State/province [136]
0
0
Lucca
Query!
Country [137]
0
0
Italy
Query!
State/province [137]
0
0
Milano
Query!
Country [138]
0
0
Italy
Query!
State/province [138]
0
0
Padova
Query!
Country [139]
0
0
Italy
Query!
State/province [139]
0
0
Palermo
Query!
Country [140]
0
0
Italy
Query!
State/province [140]
0
0
Roma
Query!
Country [141]
0
0
Korea, Republic of
Query!
State/province [141]
0
0
Goyang
Query!
Country [142]
0
0
Korea, Republic of
Query!
State/province [142]
0
0
Seongnam-si
Query!
Country [143]
0
0
Korea, Republic of
Query!
State/province [143]
0
0
Seoul
Query!
Country [144]
0
0
Mexico
Query!
State/province [144]
0
0
Baja California Norte
Query!
Country [145]
0
0
Mexico
Query!
State/province [145]
0
0
Jalisco
Query!
Country [146]
0
0
Mexico
Query!
State/province [146]
0
0
Aguascalientes
Query!
Country [147]
0
0
Mexico
Query!
State/province [147]
0
0
Durango
Query!
Country [148]
0
0
Mexico
Query!
State/province [148]
0
0
Monterrey
Query!
Country [149]
0
0
Mexico
Query!
State/province [149]
0
0
San Luis Potosi
Query!
Country [150]
0
0
Netherlands
Query!
State/province [150]
0
0
Amsterdam
Query!
Country [151]
0
0
Netherlands
Query!
State/province [151]
0
0
Eindhoven
Query!
Country [152]
0
0
Netherlands
Query!
State/province [152]
0
0
Etten-Leur
Query!
Country [153]
0
0
Netherlands
Query!
State/province [153]
0
0
Goes
Query!
Country [154]
0
0
Netherlands
Query!
State/province [154]
0
0
Groningen
Query!
Country [155]
0
0
Netherlands
Query!
State/province [155]
0
0
Hoogeveen
Query!
Country [156]
0
0
Netherlands
Query!
State/province [156]
0
0
Maastricht
Query!
Country [157]
0
0
Netherlands
Query!
State/province [157]
0
0
Nijmegen
Query!
Country [158]
0
0
Netherlands
Query!
State/province [158]
0
0
Utrecht
Query!
Country [159]
0
0
Norway
Query!
State/province [159]
0
0
Oslo
Query!
Country [160]
0
0
Norway
Query!
State/province [160]
0
0
Stavanger
Query!
Country [161]
0
0
Norway
Query!
State/province [161]
0
0
Trondheim
Query!
Country [162]
0
0
Norway
Query!
State/province [162]
0
0
Tønsberg
Query!
Country [163]
0
0
Poland
Query!
State/province [163]
0
0
Bialystok
Query!
Country [164]
0
0
Poland
Query!
State/province [164]
0
0
Bydgoszcz
Query!
Country [165]
0
0
Poland
Query!
State/province [165]
0
0
Katowice
Query!
Country [166]
0
0
Poland
Query!
State/province [166]
0
0
Krakow
Query!
Country [167]
0
0
Poland
Query!
State/province [167]
0
0
Lodz
Query!
Country [168]
0
0
Poland
Query!
State/province [168]
0
0
Poznan
Query!
Country [169]
0
0
Poland
Query!
State/province [169]
0
0
Pulawy
Query!
Country [170]
0
0
Poland
Query!
State/province [170]
0
0
Ruda Slaska
Query!
Country [171]
0
0
Poland
Query!
State/province [171]
0
0
Warszawa
Query!
Country [172]
0
0
Poland
Query!
State/province [172]
0
0
Wroclaw
Query!
Country [173]
0
0
Puerto Rico
Query!
State/province [173]
0
0
Bayamon
Query!
Country [174]
0
0
Puerto Rico
Query!
State/province [174]
0
0
Caguas
Query!
Country [175]
0
0
Romania
Query!
State/province [175]
0
0
Dolj
Query!
Country [176]
0
0
Romania
Query!
State/province [176]
0
0
Mures
Query!
Country [177]
0
0
Romania
Query!
State/province [177]
0
0
Timis
Query!
Country [178]
0
0
Romania
Query!
State/province [178]
0
0
Bacau
Query!
Country [179]
0
0
Romania
Query!
State/province [179]
0
0
Bucharest
Query!
Country [180]
0
0
Romania
Query!
State/province [180]
0
0
Constanta
Query!
Country [181]
0
0
Romania
Query!
State/province [181]
0
0
Deva
Query!
Country [182]
0
0
Romania
Query!
State/province [182]
0
0
Iasi
Query!
Country [183]
0
0
Romania
Query!
State/province [183]
0
0
Satu Mare
Query!
Country [184]
0
0
Romania
Query!
State/province [184]
0
0
Sibiu
Query!
Country [185]
0
0
Russian Federation
Query!
State/province [185]
0
0
Arkhangelsk
Query!
Country [186]
0
0
Russian Federation
Query!
State/province [186]
0
0
Barnaul
Query!
Country [187]
0
0
Russian Federation
Query!
State/province [187]
0
0
Kazan
Query!
Country [188]
0
0
Russian Federation
Query!
State/province [188]
0
0
Moscow
Query!
Country [189]
0
0
Russian Federation
Query!
State/province [189]
0
0
Nizhniy Novgorod
Query!
Country [190]
0
0
Russian Federation
Query!
State/province [190]
0
0
Penza
Query!
Country [191]
0
0
Russian Federation
Query!
State/province [191]
0
0
Saratov
Query!
Country [192]
0
0
Russian Federation
Query!
State/province [192]
0
0
Smolensk
Query!
Country [193]
0
0
Russian Federation
Query!
State/province [193]
0
0
Tumen
Query!
Country [194]
0
0
Russian Federation
Query!
State/province [194]
0
0
Yaroslavl
Query!
Country [195]
0
0
Serbia
Query!
State/province [195]
0
0
Belgrade
Query!
Country [196]
0
0
South Africa
Query!
State/province [196]
0
0
Free State
Query!
Country [197]
0
0
South Africa
Query!
State/province [197]
0
0
Gauteng
Query!
Country [198]
0
0
South Africa
Query!
State/province [198]
0
0
KwaZulu-Natal
Query!
Country [199]
0
0
South Africa
Query!
State/province [199]
0
0
Western Cape
Query!
Country [200]
0
0
South Africa
Query!
State/province [200]
0
0
Alberton
Query!
Country [201]
0
0
South Africa
Query!
State/province [201]
0
0
Cape Town
Query!
Country [202]
0
0
Spain
Query!
State/province [202]
0
0
Almería
Query!
Country [203]
0
0
Spain
Query!
State/province [203]
0
0
Barcelona
Query!
Country [204]
0
0
Spain
Query!
State/province [204]
0
0
La Coruña
Query!
Country [205]
0
0
Spain
Query!
State/province [205]
0
0
Madrid
Query!
Country [206]
0
0
Spain
Query!
State/province [206]
0
0
Mora De Ebre
Query!
Country [207]
0
0
Spain
Query!
State/province [207]
0
0
Mostoles - Madrid -
Query!
Country [208]
0
0
Spain
Query!
State/province [208]
0
0
Palma de Mallorca
Query!
Country [209]
0
0
Spain
Query!
State/province [209]
0
0
Pozuelo de Alarcon
Query!
Country [210]
0
0
Spain
Query!
State/province [210]
0
0
Sevilla
Query!
Country [211]
0
0
Spain
Query!
State/province [211]
0
0
Valladolid
Query!
Country [212]
0
0
Sweden
Query!
State/province [212]
0
0
Göteborg
Query!
Country [213]
0
0
Sweden
Query!
State/province [213]
0
0
Malmö
Query!
Country [214]
0
0
Sweden
Query!
State/province [214]
0
0
Stockholm
Query!
Country [215]
0
0
Sweden
Query!
State/province [215]
0
0
Örebro
Query!
Country [216]
0
0
Taiwan
Query!
State/province [216]
0
0
Changhua City
Query!
Country [217]
0
0
Taiwan
Query!
State/province [217]
0
0
Kaoshiung
Query!
Country [218]
0
0
Taiwan
Query!
State/province [218]
0
0
Tainan city
Query!
Country [219]
0
0
Taiwan
Query!
State/province [219]
0
0
Taoyuan
Query!
Country [220]
0
0
Turkey
Query!
State/province [220]
0
0
Ankara
Query!
Country [221]
0
0
Turkey
Query!
State/province [221]
0
0
Antalya
Query!
Country [222]
0
0
Turkey
Query!
State/province [222]
0
0
Bursa
Query!
Country [223]
0
0
Turkey
Query!
State/province [223]
0
0
Gaziantep
Query!
Country [224]
0
0
Turkey
Query!
State/province [224]
0
0
Istanbul
Query!
Country [225]
0
0
Turkey
Query!
State/province [225]
0
0
Izmir
Query!
Country [226]
0
0
Turkey
Query!
State/province [226]
0
0
Kayseri
Query!
Country [227]
0
0
United Arab Emirates
Query!
State/province [227]
0
0
Dubai
Query!
Country [228]
0
0
United Kingdom
Query!
State/province [228]
0
0
Aberdeen
Query!
Country [229]
0
0
United Kingdom
Query!
State/province [229]
0
0
Birmingham
Query!
Country [230]
0
0
United Kingdom
Query!
State/province [230]
0
0
Bristol
Query!
Country [231]
0
0
United Kingdom
Query!
State/province [231]
0
0
Coventry
Query!
Country [232]
0
0
United Kingdom
Query!
State/province [232]
0
0
Devon
Query!
Country [233]
0
0
United Kingdom
Query!
State/province [233]
0
0
Dundee
Query!
Country [234]
0
0
United Kingdom
Query!
State/province [234]
0
0
Edinburgh
Query!
Country [235]
0
0
United Kingdom
Query!
State/province [235]
0
0
Glasgow
Query!
Country [236]
0
0
United Kingdom
Query!
State/province [236]
0
0
Guildford
Query!
Country [237]
0
0
United Kingdom
Query!
State/province [237]
0
0
Hull
Query!
Country [238]
0
0
United Kingdom
Query!
State/province [238]
0
0
Livington
Query!
Country [239]
0
0
United Kingdom
Query!
State/province [239]
0
0
London
Query!
Country [240]
0
0
United Kingdom
Query!
State/province [240]
0
0
Manchester
Query!
Country [241]
0
0
United Kingdom
Query!
State/province [241]
0
0
Norwich
Query!
Country [242]
0
0
United Kingdom
Query!
State/province [242]
0
0
Nuneaton
Query!
Country [243]
0
0
United Kingdom
Query!
State/province [243]
0
0
Plymouth
Query!
Country [244]
0
0
United Kingdom
Query!
State/province [244]
0
0
St Helens
Query!
Country [245]
0
0
United Kingdom
Query!
State/province [245]
0
0
Swansea
Query!
Country [246]
0
0
United Kingdom
Query!
State/province [246]
0
0
Torquay
Query!
Country [247]
0
0
United Kingdom
Query!
State/province [247]
0
0
West Midlands
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novo Nordisk A/S
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01179048
Query!
Trial related presentations / publications
Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2019 Jul;21(7):1745-1751. doi: 10.1111/dom.13698. Epub 2019 Apr 2. Hinton W, Feher M, Munro N, Walker M, de Lusignan S. Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. Diabetes Obes Metab. 2019 Jul;21(7):1661-1667. doi: 10.1111/dom.13710. Epub 2019 Apr 11. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. Petrie JR, Marso SP, Bain SC, Franek E, Jacob S, Masmiquel L, Leiter LA, Haluzik M, Satman I, Omar M, Shestakova M, Van Gaal L, Mann JF, Baeres FM, Zinman B, Poulter NR; LEADER investigators. LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. J Hypertens. 2016 Jun;34(6):1140-50. doi: 10.1097/HJH.0000000000000890. Masmiquel L, Leiter LA, Vidal J, Bain S, Petrie J, Franek E, Raz I, Comlekci A, Jacob S, van Gaal L, Baeres FM, Marso SP, Eriksson M; LEADER investigators. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol. 2016 Feb 10;15:29. doi: 10.1186/s12933-016-0341-5. Satman I, R Rea R, Eriksson M, Mosenzon O, Pratley R, M Baeres F, D Orsted D, F Mann J; LEADER Trial Investigators. LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. J Diabetes Complications. 2016 Nov-Dec;30(8):1631-1639. doi: 10.1016/j.jdiacomp.2016.06.001. Epub 2016 Jun 3. Rutten GE, Tack CJ, Pieber TR, Comlekci A, Orsted DD, Baeres FM, Marso SP, Buse JB; LEADER Investigators. LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. Diabetol Metab Syndr. 2016 Jun 2;8:37. doi: 10.1186/s13098-016-0153-5. eCollection 2016. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013 Nov;166(5):823-30.e5. doi: 10.1016/j.ahj.2013.07.012. Epub 2013 Oct 2. Steinberg WM, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, Steen Ravn L, Moses AC, Stockner M, Baeres FM, Marso SP, Buse JB; LEADER Trial investigators. LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas. 2014 Nov;43(8):1223-31. doi: 10.1097/MPA.0000000000000229. Daniels GH, Hegedus L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann JF, Derving Karsbol J, Moses AC, Buse JB, Tuttle RM; LEADER Trial Investigators. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. Diabetes Obes Metab. 2015 May;17(5):477-86. doi: 10.1111/dom.12444. Epub 2015 Feb 23. Steinberg WM, Buse JB, Ghorbani MLM, Orsted DD, Nauck MA; LEADER Steering Committee; LEADER Trial Investigators. Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care. 2017 Jul;40(7):966-972. doi: 10.2337/dc16-2747. Epub 2017 May 5. Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornoe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. Hegedus L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbol JD, Daniels GH; LEADER Publication Committee on behalf of the LEADER Trial Investigators. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care. 2018 Mar;41(3):620-622. doi: 10.2337/dc17-1956. Epub 2017 Dec 26. Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). Am J Cardiol. 2018 Jun 15;121(12):1467-1470. doi: 10.1016/j.amjcard.2018.02.030. Epub 2018 Mar 15. Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. Circulation. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898. No abstract available. Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 2018 Aug;41(8):1663-1671. doi: 10.2337/dc17-1825. Epub 2018 Jun 13. Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care. 2018 Aug;41(8):1783-1791. doi: 10.2337/dc17-2677. Epub 2018 Jun 14. Nauck MA, Tornoe K, Rasmussen S, Treppendahl MB, Marso SP; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. Diab Vasc Dis Res. 2018 Sep;15(5):465-468. doi: 10.1177/1479164118783935. Epub 2018 Jun 27. Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornoe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care. 2018 Oct;41(10):2229-2235. doi: 10.2337/dc18-1094. Epub 2018 Aug 2. Verma S, Leiter LA, Mazer CD, Bain SC, Buse J, Marso S, Nauck M, Zinman B, Bosch-Traberg H, Rasmussen S, Michelsen MM, Bhatt DL. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation. 2018 Oct 9;138(15):1605-1607. doi: 10.1161/CIRCULATIONAHA.118.036862. No abstract available. Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation. 2018 Dec 18;138(25):2908-2918. doi: 10.1161/CIRCULATIONAHA.118.036418. Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Orsted DD, Monk Fries T, Rasmussen S, Marso SP. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516. Nauck MA, Buse JB, Mann JFE, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A; LEADER Publication Committee for the LEADER Trial Investigators. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes Obes Metab. 2019 Mar;21(3):525-532. doi: 10.1111/dom.13547. Epub 2018 Oct 25. Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Orsted DD, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Liraglutide and Glycaemic Outcomes in the LEADER Trial. Diabetes Ther. 2018 Dec;9(6):2383-2392. doi: 10.1007/s13300-018-0524-z. Epub 2018 Nov 3. Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Rea RR, Kerr Saraiva JF, Rasmussen S, Tornoe K, von Scholten BJ, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Ann Intern Med. 2019 Mar 19;170(6):423-426. doi: 10.7326/M18-1569. Epub 2018 Dec 4. No abstract available. Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, Sejersten Ripa M, Bonaca MP. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022 Jul;24(7):1288-1299. doi: 10.1111/dom.14700. Epub 2022 Apr 11. Heller SR, Geybels MS, Iqbal A, Liu L, Wagner L, Chow E. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study. Diabetologia. 2022 Jan;65(1):55-64. doi: 10.1007/s00125-021-05556-7. Epub 2021 Oct 26. Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann JFE, Pratley R, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Rossing P; LEADER Trial Investigators. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care. 2021 Apr;44(4):1020-1026. doi: 10.2337/dc20-1622. Epub 2021 Jan 27. Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, Monk Fries T, Pratley RE, Rasmussen S, Vrazic H, Zinman B, Buse JB. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Dec;22(12):2487-2492. doi: 10.1111/dom.14160. Epub 2020 Sep 4. Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 Sep;43(9):e108-e110. doi: 10.2337/dc20-0437. Epub 2020 Jul 9. No abstract available. Verma S, Bain SC, Honore JB, F E Mann J, A Nauck M, E Pratley R, Rasmussen S, Sejersten Ripa M, Zinman B, Buse JB. Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2020 Nov;22(11):2193-2198. doi: 10.1111/dom.14140. Epub 2020 Aug 12. Leiter LA, Bain SC, Bhatt DL, Buse JB, Mazer CD, Pratley RE, Rasmussen S, Ripa MS, Vrazic H, Verma S. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Sep;22(9):1690-1695. doi: 10.1111/dom.14079. Epub 2020 Jun 3. Buse JB, Bain SC, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Pratley RE, Linder M, Monk Fries T, Orsted DD, Zinman B; LEADER Trial Investigators. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care. 2020 Jul;43(7):1546-1552. doi: 10.2337/dc19-2251. Epub 2020 May 4. Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, Poulter NR, Pratley RE, Thomsen AB, Buse JB; LEADER Trial Investigators. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. J Am Coll Cardiol. 2020 Mar 17;75(10):1128-1141. doi: 10.1016/j.jacc.2019.12.063. Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O; LEADER Trial Investigators. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clin J Am Soc Nephrol. 2020 Apr 7;15(4):465-473. doi: 10.2215/CJN.11881019. Epub 2020 Mar 4. Nauck MA, Kreiner E, Rasmussen S, Saevereid HA, Buse JB; LEADER Trial Investigators. Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920. Diabetes Care. 2020 Feb;43(2):e30-e31. doi: 10.2337/dci19-0067. No abstract available. Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Orsted DD, Nauck MA. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 Dec 1;4(12):1214-1220. doi: 10.1001/jamacardio.2019.3080. Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019 Oct;42(10):1912-1920. doi: 10.2337/dc19-0415. Epub 2019 Aug 9. Tack CJ, Jacob S, Desouza C, Bain SC, Buse JB, Nauck MA, Petrie JR, Poulter NR, Pratley RE, Stegmann HVBK, Bosch-Traberg H, Startseva E, Zinman B; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. Diabetes Obes Metab. 2019 Nov;21(11):2450-2458. doi: 10.1111/dom.13826. Epub 2019 Jul 7. Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018 Apr;24(8 Suppl):S146-S155.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Global Clinical Registry (GCR, 1452)
Query!
Address
0
0
Novo Nordisk A/S
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen...
[
More Details
]
Journal
Petrie JR, Marso SP, Bain SC, Franek E, Jacob S, M...
[
More Details
]
Journal
Masmiquel L, Leiter LA, Vidal J, Bain S, Petrie J,...
[
More Details
]
Journal
Satman I, R Rea R, Eriksson M, Mosenzon O, Pratley...
[
More Details
]
Journal
Rutten GE, Tack CJ, Pieber TR, Comlekci A, Orsted ...
[
More Details
]
Journal
Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman ...
[
More Details
]
Journal
Steinberg WM, Nauck MA, Zinman B, Daniels GH, Berg...
[
More Details
]
Journal
Daniels GH, Hegedus L, Marso SP, Nauck MA, Zinman ...
[
More Details
]
Journal
Steinberg WM, Buse JB, Ghorbani MLM, Orsted DD, Na...
[
More Details
]
Journal
Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, P...
[
More Details
]
Journal
Hegedus L, Sherman SI, Tuttle RM, von Scholten BJ,...
[
More Details
]
Journal
Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Tre...
[
More Details
]
Journal
Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Mar...
[
More Details
]
Journal
Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse...
[
More Details
]
Journal
Zinman B, Marso SP, Christiansen E, Calanna S, Ras...
[
More Details
]
Journal
Nauck MA, Tornoe K, Rasmussen S, Treppendahl MB, M...
[
More Details
]
Journal
Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L...
[
More Details
]
Journal
Verma S, Leiter LA, Mazer CD, Bain SC, Buse J, Mar...
[
More Details
]
Journal
Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B,...
[
More Details
]
Journal
Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, L...
[
More Details
]
Journal
Nauck MA, Buse JB, Mann JFE, Pocock S, Bosch-Trabe...
[
More Details
]
Journal
Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen...
[
More Details
]
Journal
Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nau...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT01179048
Download to PDF